Trial Profile
A Phase 2b, Double-blind, Randomised, 5-arm, Vehicle-controlled, Dose-ranging Trial to Evaluate the Efficacy and Safety of Twice Daily Topical Application of Delgocitinib Cream 1, 3, 8, and 20 mg/g for 16 Weeks in Adult Subjects With Mild to Severe Chronic Hand Eczema
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2023
Price :
$35
*
At a glance
- Drugs Delgocitinib (Primary)
- Indications Eczema
- Focus Therapeutic Use
- Sponsors LEO Pharma
- 10 Apr 2023 Results assessing the effect of delgocitinib cream on itch, pain and nine additional key signs and symptoms reported by patients with CHE using the Hand Eczema Symptom Diary, published in the Contact Dermatitis.
- 18 May 2022 Results presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 27 Jan 2022 Results assessing efficacy, and safety of delgocitinib cream in Chronic hand eczema, published in the British Journal of Dermatology